Skip to main content
Erschienen in: Clinical Rheumatology 12/2007

01.12.2007 | Original Article

High positivity of anti-CCP antibodies in patients with Down syndrome

verfasst von: Renato M. Nisihara, Thelma L. Skare, Marília B. G. Silva, Iara T. Messias-Reason, Nanci P. Oliveira, Patricia T. Fiedler, Shirley R. R. Utiyama

Erschienen in: Clinical Rheumatology | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to evaluate the prevalence of anti-cyclic citrullinated peptide (CCP) antibodies in patients with Down’s syndrome (DS) previously tested for IgM rheumatoid factor (RF) and to correlate the results with clinical findings. Eighty-eight patients with DS previously tested for IgM-RF were divided into two groups matched for sex and age. Group A consists of 42 RF positive patients and group B of 44 RF negative patients. The presence of anti-CCP antibody was determined using a second-generation enzyme-linked immunosorbent assay. A total of 52.3% (45/86) of DS patients were positive for anti-CCP antibodies. Twenty-four patients (57.1%) of the RF positive group and 21 (47.7%) of the RF negative group presented anti-CCP circulating antibodies. The concordance between both tests was 54.6%. None of the patients had clinical evidence of rheumatoid arthritis or juvenile idiopathic arthritis. Although a high prevalence of anti-CCP antibodies was observed in DS patients, no association has been found presently with clinical disease. Careful follow-up of these patients will be necessary to clarify the real significance of these findings.
Literatur
1.
Zurück zum Zitat National Birth Defects Prevention Network (2003) Birth defects surveillance data from selected states, 1996–2000. Birth Defects Res A Clin Mol Teratol 67:729–818CrossRef National Birth Defects Prevention Network (2003) Birth defects surveillance data from selected states, 1996–2000. Birth Defects Res A Clin Mol Teratol 67:729–818CrossRef
2.
Zurück zum Zitat Leonard S, Bower C, Petterson B, Leonard H (2000) Survival of infants born with Down’s syndrome 1980–96. Paediatr Perinat Epidemiol 14:163–171CrossRefPubMed Leonard S, Bower C, Petterson B, Leonard H (2000) Survival of infants born with Down’s syndrome 1980–96. Paediatr Perinat Epidemiol 14:163–171CrossRefPubMed
3.
Zurück zum Zitat Pueschel SM, Anneren G, Durlach R et al (1995) Guidelines for optimal care of persons with Down syndrome. Acta Paediatr 84:823–827CrossRefPubMed Pueschel SM, Anneren G, Durlach R et al (1995) Guidelines for optimal care of persons with Down syndrome. Acta Paediatr 84:823–827CrossRefPubMed
4.
Zurück zum Zitat Ugazio AG, Maccario R, Notarangelo LD, Burgio GR (1990) Immunology of Down syndrome: a review. Am J Med Genet 7:202–212 Ugazio AG, Maccario R, Notarangelo LD, Burgio GR (1990) Immunology of Down syndrome: a review. Am J Med Genet 7:202–212
5.
Zurück zum Zitat Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2005) Celiac disease in children and adolescents with Down syndrome. J Pediatr 81(5):373–376CrossRef Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2005) Celiac disease in children and adolescents with Down syndrome. J Pediatr 81(5):373–376CrossRef
6.
Zurück zum Zitat Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2006) Alterations of TSH in Down syndrome patients: a hard interpretation. Rev Med Lab 46:333–337 Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2006) Alterations of TSH in Down syndrome patients: a hard interpretation. Rev Med Lab 46:333–337
7.
Zurück zum Zitat Anwar AJ, Walker JD, Frier BM (1998) Type-1 diabetes mellitus and Down’s syndrome: prevalence, management and diabetic complications. Diabet Med 15:160–163CrossRefPubMed Anwar AJ, Walker JD, Frier BM (1998) Type-1 diabetes mellitus and Down’s syndrome: prevalence, management and diabetic complications. Diabet Med 15:160–163CrossRefPubMed
8.
Zurück zum Zitat Goldacre MJ, Wotton CJ, Seagroatt V, Yeats D (2004) Cancers and immune related diseases associated with Down’s syndrome: a record linkage study. Arch Dis Child 89:1014–1017CrossRefPubMedPubMedCentral Goldacre MJ, Wotton CJ, Seagroatt V, Yeats D (2004) Cancers and immune related diseases associated with Down’s syndrome: a record linkage study. Arch Dis Child 89:1014–1017CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Padmakumar B, Evans Jones LG, Sills JA (2002) Is arthritis more common in children with Down syndrome? Rheumatology 41:1191–1193CrossRefPubMed Padmakumar B, Evans Jones LG, Sills JA (2002) Is arthritis more common in children with Down syndrome? Rheumatology 41:1191–1193CrossRefPubMed
10.
Zurück zum Zitat Yancey C, Zmijewski C, Athreya BH, Doughty RA (1984) Arthropathy of Downs’ syndrome. Arthritis Rheum 27:929–934CrossRefPubMed Yancey C, Zmijewski C, Athreya BH, Doughty RA (1984) Arthropathy of Downs’ syndrome. Arthritis Rheum 27:929–934CrossRefPubMed
11.
Zurück zum Zitat Olson JC, Bender JC, Levinson JE, Oestreich A, Loveli D (1990) Arthropathy of Down syndrome. Pediatrics 86:931–936PubMed Olson JC, Bender JC, Levinson JE, Oestreich A, Loveli D (1990) Arthropathy of Down syndrome. Pediatrics 86:931–936PubMed
12.
Zurück zum Zitat Kinnel HG (1984) Arthritis in Down’s syndrome. Br J Radiol 54:1167 Kinnel HG (1984) Arthritis in Down’s syndrome. Br J Radiol 54:1167
13.
Zurück zum Zitat Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680CrossRefPubMed Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680CrossRefPubMed
14.
Zurück zum Zitat Grahane R (1998) Hypermobility syndrome. In: Kilpell JH, Fieppe PA (eds) Rheumatology, 2nd edn. Mosby, London, S8–51.1–51.6 Grahane R (1998) Hypermobility syndrome. In: Kilpell JH, Fieppe PA (eds) Rheumatology, 2nd edn. Mosby, London, S8–51.1–51.6
15.
Zurück zum Zitat Cuadrado E, Barrena MJ (1996) Immune dysfunction in Down’s syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 78:209–214CrossRefPubMed Cuadrado E, Barrena MJ (1996) Immune dysfunction in Down’s syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 78:209–214CrossRefPubMed
16.
Zurück zum Zitat Jansen AL, van den Horst-Bruisma IE, van Shaardenburg D, Van den Stad RJ, de Konig MH, Dijkmans BA (2002) Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29:2074–2076PubMed Jansen AL, van den Horst-Bruisma IE, van Shaardenburg D, Van den Stad RJ, de Konig MH, Dijkmans BA (2002) Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29:2074–2076PubMed
17.
Zurück zum Zitat Hingh YC, Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, Vries E (2005) Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr 147:744–747CrossRefPubMed Hingh YC, Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, Vries E (2005) Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr 147:744–747CrossRefPubMed
18.
Zurück zum Zitat Franciotta D, Verri A, Zardini E, Andreoni L, Amici M, Moratti R, Nespoli L (2006) Interferon γ and interleukin-4 producing T cells in Down’s syndrome. Neurosci Lett 395:67–70CrossRefPubMed Franciotta D, Verri A, Zardini E, Andreoni L, Amici M, Moratti R, Nespoli L (2006) Interferon γ and interleukin-4 producing T cells in Down’s syndrome. Neurosci Lett 395:67–70CrossRefPubMed
19.
Zurück zum Zitat Berglin E, Padyukov L, Sundin U et al (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:303–308CrossRef Berglin E, Padyukov L, Sundin U et al (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:303–308CrossRef
20.
Zurück zum Zitat Day SM, Strauss DJ, Shavelle RM, Reynolds RJ (2005) Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 47(3):171–176CrossRefPubMed Day SM, Strauss DJ, Shavelle RM, Reynolds RJ (2005) Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 47(3):171–176CrossRefPubMed
21.
Zurück zum Zitat Ferraro AS, Newkirk MM (1993) Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 92:425–431CrossRefPubMedPubMedCentral Ferraro AS, Newkirk MM (1993) Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 92:425–431CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Newkirk MM (2002) Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 104:1–13CrossRefPubMed Newkirk MM (2002) Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 104:1–13CrossRefPubMed
24.
Zurück zum Zitat Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P (2006) Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 33:647–651PubMed Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P (2006) Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 33:647–651PubMed
25.
Zurück zum Zitat Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P (2006) Deiminated Epstein–Barr virus nuclear antigen 1 is a target of anti citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 54:733–741CrossRefPubMed Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P (2006) Deiminated Epstein–Barr virus nuclear antigen 1 is a target of anti citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 54:733–741CrossRefPubMed
26.
Zurück zum Zitat Ates A, Karaaslan Y, Aksaray S (2007) Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 26(4):499–504 (May 3)CrossRefPubMed Ates A, Karaaslan Y, Aksaray S (2007) Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 26(4):499–504 (May 3)CrossRefPubMed
27.
Zurück zum Zitat Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26(2):201–204 (Mar 30)CrossRefPubMed Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26(2):201–204 (Mar 30)CrossRefPubMed
Metadaten
Titel
High positivity of anti-CCP antibodies in patients with Down syndrome
verfasst von
Renato M. Nisihara
Thelma L. Skare
Marília B. G. Silva
Iara T. Messias-Reason
Nanci P. Oliveira
Patricia T. Fiedler
Shirley R. R. Utiyama
Publikationsdatum
01.12.2007
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 12/2007
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0606-1

Weitere Artikel der Ausgabe 12/2007

Clinical Rheumatology 12/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.